SMAD3 and familial dilated cardiomyopathy: These results suggested that ADAM17 knockdown combined with eplerenone treatment inhibited fibroblast transformation by inhibiting TGF-β1/Smad3 pathway activation, thereby reducing cardiac fibrosis and improving cardiac remodeling in DCM.